AMN Healthcare Services delivered one of its sharpest single-session moves in recent memory this week, yet short sellers have barely flinched — creating an unusual standoff between a rallying stock and a positioning picture that remains cautious.
The numbers behind Thursday's surge are striking. The stock jumped nearly 17% on August 7, closing at $36.00, building on a 7% weekly gain and an 8% month-to-date advance. The catalyst was a Q2 earnings print that landed well above Street expectations. The Nurse and Allied Solutions segment continues to be the core driver, and management's commentary on balance sheet leverage — targeting 2.0x or below for 2026 — gave investors a cleaner fundamental story to buy. Year-to-date, AMN has now more than doubled from its prior lows.
Short interest is telling a more stubborn story. At 9.8% of the free float, the short base has grown roughly 15% over the past month — a meaningful build even as the stock has climbed. The week-on-week change is effectively flat, meaning shorts did not aggressively cover into Thursday's pop. Borrowing costs remain low at 0.44%, barely moving on the week, which suggests lenders are under no pressure to recall shares. The borrow market is genuinely loose: availability runs at 603%, meaning roughly six shares are available to borrow for every one already lent out. There is no squeeze mechanism in place. Shorts can reload if they choose, and the data suggests some are doing exactly that.
Options positioning reinforces the cautious read. The put/call ratio hit 2.50 on August 7 — the highest level in the past 52 weeks — running well above its 20-day average of 2.00. That is a 1.3 standard-deviation move to the defensive side. The elevated PCR predates the earnings release, suggesting hedges were layered on into the event rather than built in its aftermath. Taken together, the lending and options data paint a picture of a market that acknowledges the rally but is not yet willing to abandon the other side of the trade.
Analyst reaction to the print has been constructive but restrained. UBS raised its target to $35 from $32 on August 7, maintaining a Neutral rating — a signal of improving confidence, not conviction. Truist Securities was more aggressive ahead of results, lifting its target to $40 from $26 in late July while keeping a Buy. The mean price target now sits at $34.29, which is fractionally below the current price of $36. That inversion is notable: the stock has run through consensus, leaving bulls arguing for further multiple expansion and bears pointing to persistent margin pressure and competitive dynamics in language services and travel nurse bill rates. The EV/EBITDA multiple of 8.7x has edged higher but remains undemanding relative to healthcare services history. Factor scores are mixed — short-score rank sits in the 21st percentile, meaning AMN scores modestly on the bearish composite, while EPS momentum over 30 days ranks in the bottom decile of the universe.
Institutional flows offer a partial clue on who is stepping in. Arrowstreet Capital nearly tripled its position in Q1 (adding 1.3 million shares), and Two Sigma added 778,000 shares in the same period. Millennium and D.E. Shaw both trimmed meaningfully — cuts of approximately 1 million and 770,000 shares respectively. The net picture is one of quantitative and systematic funds rotating in while some multi-strategy players lightened up ahead of the recovery. Insider activity has been quiet, with only a small open-market sale by the board chairman in mid-June at $31, well below current levels.
The next formal catalyst is the Q3 earnings report, scheduled for November 5. Between now and then, the key tension is whether a short base sitting near a one-month high — against a stock that has already priced in a recovery — gradually covers into strength or digs in as targets get revised higher.
See the live data behind this article on ORTEX.
Open AMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
